Alpert, they review the pharmacokinetic as well as the pharmacodynamic basis for the often increased sensitivity in geriatric patients. This article also discusses the basis for the great variability of sensitivity in these patients.
This reminded me of my recent work with pramipexole in treating resistant depressions (often electroconvulsive therapy failures) in geriatric patients who, in contrast to most studies, seemed to require and tolerate higher doses. 1 tioned in this series) has shown that prazosin, an alpha-blocker, also exceeds placebo without major side effects 2 in treating agitation in very elderly patients, we have to wonder why they are not further studied or even used by clinicians. The idea of an informed consent discussion with patients or their guardians would result in more directly facing the potential toxic effects of these medications versus the risks generated by an agitated state.
Upon reading the final article by Drs. Atri and Stern, I learned that an increasing volume of research supports giving a combination of donepezil and memantine to a patient with Alzheimer's dementia, as it has no more and perhaps even fewer side effects than standard treatment.
Do we need more treatment studies sponsored by the National Institute of Mental Health or other government agencies to help clinicians address these issues in treating their patients as we are spending billions on research looking for the pathophysiologic mechanisms of these difficult to treat disorders? We're all getting older (particularly me), and we need more effective and safer treatments for the major areas addressed in this series, because they are not going away. Also, as the population of the elderly increases, these problems will increase. Cheers!
